Mydriacyl

(Tropicamide)

ApprovedSmall molecule

FFalcon

Mydriacyl is one of 50 small molecule programs targeting Myopia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

MyopiaActive, not recruiting

CataractActive, not recruiting

EsotropiaActive, not recruiting

MyopiaApproved

Active, not recruiting

CataractPreclinical

Active, not recruiting

EsotropiaApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Mydriacyl

FFalcon

Approved

1 2

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 3

Mapracorat

Bayer

Phase 3

4 4

Tetracaine Hydrochloride

BBausch Health Americas, Inc.

Phase 3

1 5

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 6

OCS-01

QQuan Dong Nguyen

Phase 3

1 7

Zolymbus

AbbVie

Preclinical

—8

Neurontin

VViatris Specialty LLC

Preclinical

3 9

Bactroban

PPadagis LLC

Preclinical

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intraocular Pressure2 trials

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

Completed·WWake Forest University Health Sciences·Phase 1·NCT03139708·5 enrolled

Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients

Completed·SSemnan University of Medical Sciences·Phase 3·NCT04932213·98 enrolled

Cataract1 trial

Subfoveal Choroidal Thickness After Surgery for Age-related Cataracts

Completed·SSun Yat-sen University·N/A·NCT02895074·40 enrolled

Oxygenation1 trial

Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients

Completed·UUniversité de Montréal··NCT02023086·8 enrolled

Trial1 trial

Descemet Endothelial Thickness Comparison Trial

Unknown status·OOregon Health and Science University·Phase 4·NCT02373137·38 enrolled

Esotropia1 trial

Cycloplegic Refraction in Pediatric Patients With Esotropia

Unknown status·—·Phase 4·NCT06077682·100 enrolled

5 more indications

Children1 trial

Cycloplegic Refraction Among Children

Completed·—·Phase 4·NCT05442801·55 enrolled

Dilation1 trial

Wearing-Off Period of Pharmacological Dilation and Anisocoria

Completed·PPrisma Health-Upstate·Phase 4·NCT05238233·11 enrolled

Myopia1 trial

Study of Myopia Prevention in Children With Low Concentration of Atropine

Unknown status·MMin-Sheng General Hospital·Phase 4·NCT00541177·60 enrolled

Parkinson's Disease1 trial

Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients

Completed·NNeuroHealing Pharmaceuticals Inc.·Phase 2·NCT00761137·19 enrolled

Unspecified1 trial

The Effect of Brimonidine

Completed·WWake Forest University Health Sciences·Phase 4·NCT03959176·13 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

MYDRIACYL

NDA NDA012111

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Tropicamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tropicamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tropicamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA012111). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Falcon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFalcon

Mydriacyl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intraocular Pressure2 trials

Cataract1 trial

Oxygenation1 trial

Trial1 trial

Esotropia1 trial

Children1 trial

Dilation1 trial

Myopia1 trial

Parkinson's Disease1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News